Tasigna and Gleevec drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Tasigna (nilotinib hydrochloride monohydrate) and Gleevec (imatinib mesylate). Common drug interactions include dyspnoea among females and drug ineffective among males.
The phase IV clinical study analyzes what interactions people have when they take Tasigna and Gleevec. It is created by eHealthMe based on reports of 1,123 people who take the same drugs from the FDA, and is updated regularly.
What is Tasigna?
Tasigna has active ingredients of nilotinib hydrochloride monohydrate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 31,535 Tasigna users. Check the latest studies of Tasigna.
What is Gleevec?
Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 35,415 Gleevec users. Check the latest studies of Gleevec.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
1,123 people who take Tasigna and Gleevec together, and have interactions are studied.
What are the common drug interactions of Tasigna and Gleevec, by gender? *
What are the common drug interactions of Tasigna and Gleevec, by age (0-1 to 60+)? *
What are the existing conditions these people have? *
* Approximation only. Some reports may have incomplete information.
Do you take Tasigna and Gleevec?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Tasigna and Gleevec:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Tasigna:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Gleevec:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Tasigna and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Gleevec and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .
- O'rafferty C, McElligott F, Storey L, O'marcaigh A, Smith O, "Pneumatosis intestinalis and imatinib mesylate", Annals of hematology, 2014 Oct .
How the study uses the data?
The study uses data from the FDA. It is based on nilotinib hydrochloride monohydrate and imatinib mesylate (the active ingredients of Tasigna and Gleevec, respectively), and Tasigna and Gleevec (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Prilosec cause Bronchitis Acute? - 2 seconds ago
- Could Dexamethasone cause Cardiotoxicity? - 6 seconds ago
- Drug interactions of Ativan and Citalopram Hydrobromide - 7 seconds ago
- Diaphragmatic Hernia and drugs of ingredients of lorazepam - 10 seconds ago
- Birth Control and Loss Of Libido - 13 seconds ago
- Could Methotrexate cause Breast Cancer Aggravated? - 14 seconds ago
- Could Myozyme cause Oedema Peripheral? - 16 seconds ago
- Fracture Delayed Union and drugs of ingredients of fexofenadine hydrochloride - 19 seconds ago
- Acne and Skin Tightness - 35 seconds ago
- Could Furosemide cause Rash Erythematous? - 40 seconds ago